Background
More than 47 million people worldwide are affected by dementia, and the number is estimated to double every 20 years with the increases in life expectancy [
1,
2]. Alzheimer’s disease (AD) accounts for 60 to 70% of all dementia cases [
3], and the accumulation of toxic forms of β-amyloid (Aβ) and tau neurofibrillary tangles in the brain is considered the main pathological mechanism. According to epidemiological studies, sleep difficulties are significantly more common among the elderly, with a prevalence of 36 to 69% [
4]. When left untreated, sleep difficulties are associated with severe adverse consequences, ranging from poor mental health to cardiovascular disease [
5]. According to the Neuropsychiatric Inventory (NPI)-sleep subitem, chronic sleep disturbance (CSD) consists of 8 aspects, including difficulty falling asleep, superficial sleep, early awakening, interrupted sleep, abnormal nighttime behavior, excessive daytime sleepiness, getting up at night, and other nocturnal abnormal behaviors. A bidirectional relationship exists between sleep and neurodegenerative disorders, such as AD, caused by Aβ and tau pathologies [
6]. Extended periods of wakefulness or sleep deprivation were found to regulate the extracellular release of both Aβ [
7,
8] and tau [
9,
10]. Besides Aβ pathology, another biologically potential mechanism linking CSD and dementia risk is inflammatory response activation, which is thought to be an early event associated with the onset and clinical course of AD [
11]. The mechanism by which inflammation associated with AD pathology regulates the relevance of CSD to cognitive function remains unclear. A better understanding of the mechanism of the effect of CSD on cognitive progression can help identify potential targets for dementia prevention.
Previous studies have shown that sleep disturbance can influence the hypothalamus–pituitary–adrenal (HPA) axis and the sympathetic nervous system (SNS), which together alter the profile of proinflammatory gene expression [
12], and induce increases in interleukin 6 (IL-6), C-reactive protein (CRP) [
13], tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β) [
14], and vascular cell adhesion molecule-1 (VCAM-1) [
15]. Growing evidences demonstrated that sleep disturbance links with systemic inflammation and that neutrophils, as a marker of the ongoing non-specific inflammation and the first-line innate immune cell, can induce the uncontrolled release of toxic substances including inflammatory cytokines and tissue-damaging materials [
16]. The ratio of neutrophil-to-lymphocyte has been repeatedly shown to be associated with obstructive sleep apnea [
16‐
18]. Activation of neutrophils induces the release of neutrophil extracellular traps (NETs), leading to vascular destabilization [
19], breakdown of the blood–brain barrier (BBB) [
20], and vulnerability of the brain to damage [
21]. Meanwhile, inflammatory cytokines also promote vascular permeability, neutrophil adhesion, and migration [
22]. These findings suggested the importance of neutrophils in CSD, and we would focus on the effects of neutrophils on the association of CSD and cognitive function. In the present study, the longitudinal analysis showed the association of CSD with cognitive progression, and transcriptomics enrichment analysis revealed the activated neutrophil pathways in cognitively progressive subjects with CSD, which was echoed by analyses on blood neutrophils. The correlation between the neutrophil pathway and brain tau burden may reveal the mechanism, by which neutrophil activation triggers tau pathology to impair cognitive function in CSD.
Methods
Subjects
The data on 2272 adults were retrieved from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (
http://adni.loni.usc.edu). ADNI is a multi-site dataset launched in 2003 and designed to test the clinical symptoms, imaging, genetic, and biochemical biomarkers of AD. Data collection and sharing in ADNI were approved by the institutional review boards of all participating institutions. Written informed consent was obtained from all participants or their guardians in accordance with the Declaration of Helsinki. The participants are older adults aged 55–90. Each participant had an in-person neuropsychological assessment interview at baseline and annual follow-up [
23,
24]. The inclusion and exclusion criteria are shown in the flow chart (Additional file
1). The subjects in this study received an NPI-sleep assessment [
25,
26] at least twice in follow-up visits, with an interval of 6 months. The participants reporting normal sleep at each follow-up were selected for the normal sleep group (
n = 528), and the subjects reporting sleep difficulties at baseline and follow-up (≥ 2 times in total) were selected for the CSD group (
n = 256). To avoid information bias, patients who reported sleep disturbance only once were excluded. Finally, a total of 784 non-dementia elderly were included in this study. Detailed NPI-sleep assessments are provided in Additional file
2.
Cognitive assessments included the Mini-Mental State Examination (MMSE), the Alzheimer’s Disease Assessment Scale-cognitive (ADAS-cog), the Functional Activities Questionnaire (FAQ), the ADNI-MEM for memory, and the Montreal Cognitive Assessment (MoCA). In the ADNI, cognitively normal subjects had MMSE scores of 24–30, a Clinical Dementia Rating (CDR) of 0, and no memory complaints. Subjects with mild cognitive impairment (MCI) had MMSE scores of 24–30, a CDR score of 0.5, an informant-reported memory complaint, and objective evidence of memory loss. Through follow-up, dementia was diagnosed with MMSE scores of 20–26, a CDR score of 0.5–1, and subjective memory concern as reported by the subject, study partner, or clinician. The detailed criterion can be found in Additional file
2.
Individuals had in-person interviews at baseline and follow-up per 6 months, and the follow-up time was up to 168 months (28 times). A total of 784 non-dementia elderly were involved in this study at baseline, which included normal cognitive and MCI subjects. Through follow-up, cognitively stable individuals were defined as (1) stable normal cognitive, (2) stable MCI, or (3) MCI reversing into cognitively normal. Meanwhile, cognitively progressive individuals were defined as (1) MCI progressing into dementia or (2) cognitively normal progressing into MCI or dementia.
Routine blood test
After fasting overnight, the participants’ blood was collected in the morning using vacuum tubes with ethylene diamine tetraacetic acid (EDTA). The blood samples were then sent for analysis on the same day of collection for routine blood test, including blood neutrophil percentage.
APOE genotype
DNA was extracted with the QIAamp®DNA Blood Mini Kit and amplified by the polymerase chain reaction (PCR) with forward primers 5′-ACGGCTGTCCAAGGAGCTG-3′ (rs429358) and 5′-CTCCGCGATGCCGATGAC-3′ (rs7412). APOE genotype was performed through restriction fragment length polymorphism (RFLP) technology.
Hippocampal volume
Annual change rates of hippocampal volumes were measured longitudinally in 198 subjects who had ≥ 3 available MRI assessments provided by ADNI imaging data. The methodology details of measuring hippocampal volumes are in the Additional file
3 [
27].
CSF AD type and inflammatory biomarkers
Before analysis, all concentrations were normalized into Z scores, and outliers beyond ± 3δ were excluded. The CSF from 771 subjects had typical AD biomarkers, including Aβ42, p-tau, and t-tau proteins. These biomarkers were detected using a fully automated and highly standardized Roche Elecsys immunoassay. Meanwhile, the CSF from 189 subjects had inflammatory factors, including tumor necrosis factor receptor 1,2 (TNFR1,2); transforming growth factor 1,2,3 (TGFβ1,2,3); interleukin 6,7,21 (IL6,7,21); intercellular adhesion molecule 1 (ICAM1); and VCAM1. These inflammatory markers were detected using commercially available multiplex immunoassays (Millipore Sigma, Burlington, MA) modified for CSF analyte levels.
Blood-based microarray profiling and analysis
The PAXgene Blood RNA Kit (Qiagen Inc., Valencia, CA, USA) was used to purify total RNA from the whole blood collected in a PAXgene Blood RNA Tube. The Affymetrix Human Genome U219 Array (Affymetrix, Santa Clara, CA, USA) was used for expression profiling in ADNI. The quality of gene expression data, including sample quality, hybridization, and overall signal quality, was analyzed using Affymetrix Expression Console software and Partek Genomic Suite 6.6. Raw expression values were pre-processed using the robust multichip average (RMA) normalization method.
Enrichment analysis was performed on 88 cognitively stable and 54 cognitively progressive subjects with CSD to investigate the activated pathways for cognitive progression. Gene set enrichment analysis (GSEA) [
28] in R was used to screen the biological process (BP) of the Gene Ontology (GO) term through the c5.go.bp.v7.5.symbols.gmt in the Molecular Signatures Database (MSigDB) [
28], the GO-Biological-Process-2018.txt in the Enrichr database as a reference gene set, and the Disease-Perturbations-from-GEO-up.txt in the Enrichr database [
29] for the pathway term between the groups. A value of adjusted
p < 0.05 was considered significant.
Statistical analyses
The Mann–Whitney U test was used for continuous variables with non-normal distributions, while the chi-square test was used for categorical variables to test the differences between the groups.
The linear mixed-effects model depicted the effects of CSD on longitudinal clinical outcomes, including cognitive function and social activity function. The model included random slope and intercept terms for each participant. The effect of neutrophils on cognitive function was demonstrated using hierarchical regression. The risk factor of CSD for cognitive progression was predicted using a time-dependent Cox proportional hazards model. To control for confounding by multiple factors, such as tau burden including CSF t-tau and p-tau, and other psychiatric symptoms including depression, appetite, aberrance, irritability, disinhibition, elation, and agitation, were all included in the Cox regression model. To eliminate the difference caused by a range of cognitive function between normal and MCI, besides demographic factors, baseline global cognition score (MMSE) was incorporated in the Cox regression model to assess the cognitive progression risk of CSD or neutrophil. A restricted cubic spline (RCS) curve was used to explore the association between blood neutrophils and cognitive outcome. RCS allows threshold identification of neutrophils on cognitive progression risk. According to the threshold of 61.33, we then divided the cohort into two subgroups (low neutrophil group < 61.633% versus high neutrophil group > 61.633%). Additionally, a Kaplan–Meier curve was used to plot the risk of cognitive progression. To determine annual change rates in cognition and hippocampal volume, we used the fitted linear mixed models with MMSE, ADAS-cog, FAQ, MoCA, ADNI-MEM, and hippocampal volumes as dependent variables and time (years from baseline) as independent variables, controlling for random intercept and slope. Then, a slope for the annual change rate was created for each subject. Longitudinal analyses were restricted to subjects with at least 3 time points.
Routine blood test of neutrophil and CSF inflammatory factors including TNFR1,2; TGFβ1,2,3; IL-6,7,21; ICAM1; and VCAM1 were compared between the normal and CSD groups using the Mann–Whitney U test. The Benjamini–Hochberg correction was used to adjust the p-value.
We used analysis of covariance (ANCOVA) to test whether CSF t-tau or p-tau positivity aggravated the association between CSD and hippocampal atrophy, after controlling for the main effects of sleep, tau burden (CSF p-tau or t-tau), age, gender, education, APOE, and intracranial volume. p-tau positivity was defined as p-tau > 21.8 pg/mL, and t-tau positivity was defined as t-tau > 245 pg/ml. The p-value was corrected using a Bonferroni correction with an α-threshold of 0.025.
Mediation analysis was used to explore what pathways mediated the link between blood neutrophils and cognitive function. Through exploratory analysis, we assigned X as the blood neutrophil percentage, M (mediator) as brain tau burden (CSF t-tau or p-tau at baseline), and Y as the outcome (cognitive function and social activity function at 2-year follow-up). We then interpreted the total effect as the amplitude of neutrophils in cognitive progression, both directly and through tau pathology intermediates. Next, we estimated the effects of the tau burden on the cognitive outcome after observing the association for a potential mediator. Age, education, gender, and APOE genotype were included as covariates, and the total, direct, and indirect effects were estimated using model 4 (mediation) of the PROCESS macro by the bruceR package in R with a bootstrapping module of 1000 iterations.
The statistical significance of all tests had a p-value of < 0.05. All analyses were performed using SPSS 17.0 or R version 4.2.0.
Discussion
The present study had four main findings. First, CSD could significantly affect cognitive function. Second, we found significant effects of blood neutrophils on cognitive progression induced by CSD. Third, tau burden mediated the association of blood neutrophils with cognitive function and increased the CSD-related risk of left hippocampus atrophy. Fourth, neutrophil-related inflammatory factors were elevated and correlated with tau burden in cognitively progressive elderly with CSD.
Our results were consistent with previous longitudinal researches showing that CSD can predict cognitive progression [
30,
31]. We found a significant difference in cognitive function between the normal sleep and CSD groups after 14 years of follow-up. Sleep difficulties have also been reported to link to an increased risk of AD. A study of 20 participants infused with C-leucine to measure Aβ kinetics showed that acute sleep deprivation increased the overnight Aβ38, Aβ40, and Aβ
42 levels by 25 to 30% [
32]. Pathologically high p-tau and gliosis were also detected in the hippocampus of CSD mice [
33]. Unlike previous researches, we found no significant changes in Aβ, t-tau, or p-tau levels in CSD subjects, but only in cognitively progressive elderly, whether they had CSD or not. This finding suggests that AD pathology is not the main characteristic pathology of cognitive decline in CSD but is closely related to it.
The GSEA revealed neutrophil activation and AD pathology as potential pathways. Tauopathy, a typical pathological feature of AD, has been shown to cause sleep disturbance. Sleep disruption has also been observed in the transgenic mouse model with overexpressed human tau mutation [
34]. Notably, we found significant changes in t-tau and p-tau levels in the cognitively progressive subjects with CSD. Relative to tau pathology, the activated neutrophil pathway was less studied. Previous studies showed that social stress upregulates inflammatory gene expression in the leukocyte transcriptome [
35]. A study of partial night sleep deprivation also found a shift in leukocyte transcriptional profiles towards the expression of genes associated with cellular senescence [
36]. We found that blood neutrophil was increased in cognitively progressive subjects with CSD. Similarly, the hyperactive neutrophil state has also been associated with the rate of cognitive progression [
37]. According to the Framingham Heart Study, individuals with a higher neutrophil-to-lymphocyte ratio were at greater risk of subsequent dementia [
38]. Our study found a significant risk of cognitive progression related to blood neutrophil levels in individuals with CSD.
Next, we investigated the interaction between the two pathways: AD pathology and neutrophil activation, and how this interaction contributed to the cognitive progression of CSD. The mediation analysis showed that t-tau and p-tau mediated the association between blood neutrophil and cognitive progression, and the effects varied from 21 to 36%. The interaction analysis showed that in the background of high blood neutrophil levels, high CSF t-tau and p-tau could exacerbate the effect of CSD on left hippocampal atrophy. Thus, we hypothesized that neutrophil-related neuro-immunity could possibly trigger or aggravate tau pathology, contributing to left hippocampal atrophy and subsequent cognitive progression in CSD.
Through hierarchical regression, we found that blood neutrophil impacted the annual change in cognitive function independently of CSF t-tau and p-tau levels, despite the small values of
R2 change between the models with and without neutrophil. The possible mechanism is that neutrophil activation in CSD begins at the initial stage, then migrates to the perivascular space of the brain and triggers tau pathology at last, which maybe explain the small but significant effect of neutrophil on cognitive progression. Therefore, we predicted that neutrophil downstream inflammatory factors might have direct effects on cognitive progression through tau pathology. Neutrophils have a very short life cycle of up to 6 days in peripheral circulation [
39]. In typical inflammation, neutrophils are cleared when the initial inflammatory insult is resolved. However, in CSD, neutrophils are recruited by chemokines, such as interleukin 8 (IL8) and C5a complement, and migrate into the peri-cerebrovascular space. As a result, neutrophils can adhere to endothelial cells, cross the blood–brain barrier, and release inflammatory factors that cause neuronal damage [
40].
We found four factors that were significantly increased in CSF, including ICAM1, VCAM1, TNFR2, and TGFβ1. ICAM1 and VCAM1 required for neutrophil adhesion and trans-endothelial migration are highly expressed in endothelial cells [
41]. TNFR2 is mainly expressed in immune cells, such as neutrophils, and acts as a potent pro-inflammatory cytokine. TGFβ1 has been implicated in myeloid cell activation, particularly neutrophil activation and degranulation [
42]. Due to the neutrophil-adherent and inflammatory nature of these four factors, their upregulation suggests that the activation of the neutrophil downstream pathway occurs during the cognitive progression of CSD. Moreover, their levels correlated with CSF t-tau and p-tau, indicating that the activated neutrophil pathway was closely related to tau burden and brain function. Similar results from a large cohort study found that higher levels of CSF ICAM1 increased the risk of developing AD dementia and were associated with increased CSF levels of t-tau and p-tau [
43]. Furthermore, chronic TNF treatment increased the release of toxic extracellular protein aggregates linking to AD pathology [
44]. The above findings indicate that neutrophil-associated inflammatory cytokines may induce synergistic neurotoxicity that exacerbates neurodegeneration.
The present study had some limitations. Due to the lack of follow-up data on blood neutrophils, the trend of blood neutrophils in CSD was unclear. Also, only CSF t-tau and p-tau analysis was performed but not tau PET imaging, which limited the investigation of regional tau pathology in CSD. Additionally, this study included both cognitively normal and MCI subjects at baseline, which may have affected the population heterogeneity bias. So, the baseline cognitive function score has been incorporated into the Cox regression analysis to eliminate cognitive bias. Blood neutrophil and CSF tauopathy were identified as potential key pathways in the ADNI cohort, and future multi-cohort studies are needed for further validation.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.